PRIMENENIE VNUTRIVENNOGO ChELOVEChESKOGO IMMUNOGLOBULINA V REVMATOLOGII


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

For many years, non-steroidal anti-inflammatory drugs, glucocorticoids and immunosuppressants have been the mainstay of therapy of rheumatic diseases. The situation has changed dramatically with the emergence of genetically engineered biologic drugs, which brought disease management to a new level. Therapy with intravenous human immunoglobulin (IVIG) has been and continues to be essential in a number of diseases. The article discusses the indications for the use of IVIG in rheumatology from the perspective of modern concepts of the mechanism of action of the drug, dosage regimen, the benefits and adverse reactions; the analysis of domestic and foreign literature on this issue is performed.

Full Text

Restricted Access

References

  1. Насонов Е.Л., Соловьев С.К. Перспективы применения моноклональных антител к в-лимфоцитам (ритуксимаб) при воспалительных ревматических заболеваниях. Научно-практическая ревматология. 2007;1:4-8.
  2. Насонов Е.Л. Внедрение высоких медицинских технологий в ревматологии: проблемы и решения. Научно-практическая ревматология. 2008;2:4-5.
  3. Vaitla P.M., McDermott E.M. The role of high-dose intravenous immunoglobulin in rheumatology. Rheumatology (Oxford). 2010;49(6):1040-48. doi: 10.1093/rheumatology/keq021. Epub 2010 Feb 23.
  4. Gelfand E.W. Intravenous immune globulin in autoimmune and inflammatory diseases N. Engl. J. Med. 2012;367(21):2015-25. doi: 10.1056/NEJMra1009433.
  5. Durandy A., Kaveri S.V., Kuijpers T.W., et al. Intravenous immunoglobulins - understanding properties and mechanisms. Clin. Exp. Immunol. 2009;158(Suppl 1):2-13. doi: 10.1111/j.1365-2249.2009.04022.x.
  6. Ballow M., Notarangelo L., Grimbacher B., et al. Immunodeficiencie. Clin. Exp. Immunol. 2009;158(Suppl 1):14-22. doi: 10.1111/j.1365-2249.2009.04023.x.
  7. Gupta M., Noel G.J., Schaefer M., et al. Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J. Clin. Immunol. 2001;21(3):193-99.
  8. Basta M. Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition. Mol. Immunol. 2008;45(16):4073-79. doi: 10.1016/j. molimm.2008.07.012. Epub 2008 Aug 15.
  9. Shoenfeld Y., Katz U. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity. 2005;38(2):123-37.
  10. Sapir T., Blank M., Shoenfeld Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann N Y Acad. Sci. 2005; 1051:743-78.
  11. Le Pottier L., Sapir T., Bendaoud B., et al. Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann N Y Acad. Sci. 2007;1110:426-32.
  12. Zandman-Goddard G., Blank M., Shoenfeld Y. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside. Lupus. 2009;18(10):884-88. doi: 10.1177/0961203309106921.
  13. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev. Immunol. 2008;26:513-33. doi: 10.1146/ annurev.immunol.26.021607.090232.
  14. Kaneko Y., Nimmerjahn F., Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313(5787):670-73.
  15. Adams H.P. Stroke: a vascular pathology with inadequate management. J. Hypertens. 2003;21(Suppl. 5):S3-7.
  16. Arumugam T.V., Tang S.C., Lathia J.D., et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc. Natl. Acad. Sci. USA. 2007;104(35): 14104-109.
  17. Gross K.L., Lu N.Z., Cidlowski J.A. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol. 2009;300(1-2):7-16. doi: 10.1016/j. mce.2008.10.001. Epub 2008 Oct 19.
  18. Katz U, Achiron A., Sherer Y., Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007;6(4):257-59.
  19. Zandman-Goddard G., Levy Y., Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin. Rev. Allergy Immunol. 2005;29(3):219-28.
  20. Jean R., Bastard E., Cretel E., Lefevre P., Durand J.M. Intravenous immunoglobulin and antiphospholipid syndrome: comment on the article by Erkan et al. Arthritis Rheum. 2004;50(8):2711-132.
  21. Wolberg A.S., Kon R.H., Monroe D.M., Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J. Hematol. 2000;65(1):30-4.
  22. Pyne D., Ehrenstein M., Morris V. The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology (Oxford). 2002;41(4):367-74.
  23. Leong H., Stachnik J., Bonk M.E., Matuszewski K.A. Unlabelled uses of intravenous immunoglobulin. Am J Health Syst Pharm. 2008;65(19):1815- 24. doi: 10.2146/ajhp070582.
  24. Furusho K., Sato K., Soeda T., et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1983;2(8363):1359.
  25. Oates-Whitehead R.M., Baumer J.H., Haines L., et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2003;(4):CD004000.
  26. Hartung H.P., Mouthon L., Ahmed R., et al. Clinical applications of intravenous immunoglobulins (IVIg) - beyond immunodeficiencies and neurology. Clin. Exp. Immunol. 2009;158(Suppl 1 ):23-33. doi: 10.1111/j.1365-2249.2009.04024.x.
  27. Al-Mayouf S.M., Laxer R.M., Schneider R., et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol. 2000;27(10):2498-503.
  28. Permal S., Wechsler B., Cabane J., et al. Treatment of stills disease in adults with intravenous immunoglobins. Rev. Med. Interne. 1995;16(4):250-54.
  29. Vignes S., Wechsler B., Amoura Z., et al. Intravenous immunoglobulin in adult Still's disease refractory to non-steroidal antiinflammatory drugs. Clin Exp Rheumatol. 1998;16(3):295-98.
  30. Prieur A.M., Adleff A., Debre M., et al. High dose immunoglobulin therapy in severe juvenile chronic arthritis: longterm follow up in 16 patients. Clin. Exp Rheumatol. 1990; 8(6):603-08.
  31. Silverman E.D., Cawkwell G.D., Lovell D.J., et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomised placebo controlled trial. J Rheumatol. 1994;21(12):2353-58.
  32. Zandman-Goddard G., Shoenfeld Y. Infections and SLE. Autoimmunity. 2005;38(7):473-85.
  33. Levy Y., Sherer Y., George J., Rovensky J., et al. Intravenous immunoglobulin treatment of lupus nepritis. Semin Arthritis Rheum. 2000;29(5):321-27.
  34. Caccavo D., Vaccaro F., Ferri G.M., et al. Antiidiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. J. Autoimmun. 1994;7(4):537-48.
  35. Shoenfeld Y., Rauova L., Gilburd B., et al. Efficacy of IVIG affinitypurified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol. 2002;14(11):1303-11.
  36. Krause I., Blank M., Sherer Y., et al. Induction of oral tolerance in experimental antiphospholipid syndrome by feeding with polyclonal immunoglobulins. Eur. J. Immunol. 2002;32(12): 3414-24.
  37. Su J., Hua X., Concha H., Svenungsson E., et al. Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatology (Oxford). 2008;47(8):1144-doi: 10.1093/rheumatology/ken120. Epub 2008 Jun 3.
  38. Решетняк Т.М. Рекомендации по лечению антифосфолипидного синдрома. [Интернет]. ФГБУ «НИИ ревматологии им.В.А.Насоновой» РАМН [доступ от 27.11.13]. Доступ по ссылке rheumatolog.ru files/natrec11.pdf.
  39. Насонов Е.Л. Профилактика и лечение антифосфолипидного синдрома: современные рекомендации и перспективы. [Интернет]. ФГБУ «НИИ ревматологии им.В.А.Насоновой» РАМН [доступ от 27.11.13]. Доступ по ссылке http://rheuma-tology.org.ua/blog/articles/588
  40. Carreras L.D., Perez G.N., Vega H.R., Casavilla F. Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin. Lancet. 198813;2(8607):393-94.
  41. Branch D.W., Peaceman A.M., Druzin M., et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol. 2000;182(1 Pt 1): 122-27.
  42. Perricone R., De Carolis C., Kröegler B., et al. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology (Oxford). 2008;47(5):646-51. doi: 10.1093/rheumatology/ken046. Epub 2008 Mar 17.
  43. Mehdi A.A., Uthman I., Khamashta M. Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future. Eur. J. Clin. Invest. 2010;40(5):451-64. doi: 10.1111/j. 1365-2362.2010.02281.x. Epub 2010 Mar 25.
  44. Ruiz-Irastorza G., Khamashta M.A. Lupus and pregnancy: integrating clues from the bench and bedside. Eur J Clin Invest. 2011 Jun;41(6):672-doi: 10.1111/j.1365-2362.2010.02443.x. Epub 2010 Dec 15.
  45. Sciascia S., Giachino O., Roccatello D. Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. Clin. Exp. Rheumatol. 2012;30(3):409-13.
  46. Штивельбанд И.Б., Кондратьева Л.В., Решетняк Т.М. Применение внутривенного иммуноглобулина при тромбоцитопении у больных с антифосфолипидным синдромом. Научно-практическая ревматология. 2004;3:93-8.
  47. Blank M., Anafi L., Zandman-Goddard G., et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol. 2007;19(7):857-65.
  48. Макацария А.Д., Бицадзе В.О., Хизроева Д.Х. Катастрофический антифосфолипидный синдром и тромботический «шторм». Сибирский медицинский журнал. 2010;25(4, выпуск 2);118-23.
  49. Cervera R. Lessons from the «Euro-Phospholipid» project. Autoimmun Rev. 2008;7(3):174-78. doi: 10.1016/j.autrev.2007.11.011. Epub 2007 Dec 3.
  50. Bucciarelli S., Cervera R., Espinosa G., et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. Autoimmun Rev. 2006;6(2):72-5.
  51. Asherson R.A., Cervera R., Piette J.C., et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore). 2001;80(6):355-77.
  52. Dalakas M.C., Illa I., Dambrosia J.M., et al. A controlled trial of high dose immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med. 1993;329(27):1993-2000.
  53. Cherin P., Herson S. Immunoglobulins or plasma exchange? New treatment methods in polymyositis and dermatomyositis: plasma exchange and intravenous immunoglobulins. Ann Med. Interne (Paris). 1993;144(8):521-25.
  54. Danieli M.G., Malcangi G., Palmieri C., et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum. Dis. 2002;61(1):37-41.
  55. Cherin P., Piette J.C., Wechsler B., et al. Intravenous immunoglobulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adults. J. Rheumatol. 1994;21(6):1092-97.
  56. Nacci F., Righi A., Conforti M.L., et al. !ntravenous immunoglobulins improve the function and ameliorate join involvement in systemic sclerosis: a pilot study. Ann Rheum Dis. 2007;66(7):977-79.
  57. Amital H., Rewald E., Levy Y., et al. Fibrosis regression induced by intravenous immu noglobulin treatment. Ann Rheum Dis. 2003;62(2):175-77.
  58. Martinez V., Cohen P., Pagnoux C., et al. French Vasculitis Study Group. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic antibodies. Arthritis Rheum. 2008;58(1):308-17. doi: 10.1002/art.23147.
  59. Levy Y., Sherer Y., George J., Langevitz P., et al. Serological and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. !nt Arch Allergy Immunol. 1999 Jul; 119(3):231-38.
  60. Jayne D.R., Lockwood C.M. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol. 1996;35(11):1150-53.
  61. Richter C., Schnabel A., Csernok E., et al. Treatment of anti-neutrophii cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin. Exp. Immunol. 1995;101(1):2-7.
  62. Hamilos D.L., Christensen J. Treatment of Churg-Strauss syndrome with high dose intravenous immunoglobulin. J Allergy Clin Immunol. 1991;88(5):823-24.
  63. Tsurikisawa N., Taniguchi M., Saito H., et al. Treatment of Churg-Strauss syndrome with high dose intravenous immunoglobulin. Ann Allergy Asthma !mmunol. 2004;92(1):80-7.
  64. Emery P., Spath P., Affentranger P. A placebo controlled double blind study of high dose intravenous immunoglobulin therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 1996;39:1027-29 [abstract].
  65. Kanik K.S., Yarboro C.H., Naparstek Y., et al. Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritis. Arthritis Rheum. 1996;39(6): 1027-29.
  66. Zeuner R.A., Schroeder J.O., Schröder F., Euler H.H. Successful application of high dose intravenous immunoglobulins in Sjogren's syndrome associated arthritis. Ann Rheum Dis. 1995;54(11):936.
  67. Rajabally Y.A., Seow H., Abbott R.J. Immunoglobulin-responsive dysauto-nomia in Sjogren's syndrome. J Neurol. 2007;254(5):674-75.
  68. Smith A.J., Jackson M.W., Wang F., et al. Neutralization of muscarinic receptor autoantibodies by intravenous immunoglobulin in Sjogren syndrome. Hum !mmunol. 2005;66(4): 411-16.
  69. Seider N., Beiran I., Scharf J., Miller B. Intravenous immunoglobulin therapy for resistant ocular Behcet's disease. Br J Ophthalmol. 2001;85(11):1287-88.
  70. Kaaja R., Julkunen H. Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment or the editorial by Buyon et al. Arthritis Rheum. 2003;48(1):280-1; author reply 281-82.
  71. Bouchra A., Benbouazza K., Hajjaj-Hassouni N. Guillain-Barre in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy. Clin Rheumatol. 2009;28(Suppl 1):S53-5. doi: 10.1007/s10067-009-1154-57. Epub 2009 Mar 11.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies